| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| foundationone liquid cdx fda | 0.7 | 0.9 | 8655 | 6 | 28 |
| foundationone | 0.12 | 0.6 | 1741 | 70 | 13 |
| liquid | 1.83 | 0.6 | 8393 | 20 | 6 |
| cdx | 0.39 | 0.3 | 2283 | 81 | 3 |
| fda | 1.14 | 0.5 | 9839 | 48 | 3 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| foundationone liquid cdx fda | 0.94 | 0.6 | 3040 | 22 |
| foundationone liquid cdx fda approval | 1.96 | 0.2 | 2711 | 2 |
| foundationone liquid cdx f1 liquid cdx | 0.87 | 0.1 | 1431 | 39 |
| foundationone liquid cdx test | 1.62 | 0.4 | 6132 | 27 |
| foundationone cdx fda approval | 1.04 | 0.2 | 4230 | 15 |
| foundationone liquid cdx cpt code | 1.05 | 0.4 | 1055 | 12 |
| foundationone liquid cdx gene list | 1.08 | 1 | 8019 | 63 |
| foundation one cdx liquid | 0.17 | 0.7 | 2928 | 95 |
| foundationone liquid cdx ssed | 0.91 | 0.9 | 2456 | 68 |
| foundationone liquid cdx 添付文書 | 1.61 | 0.4 | 1579 | 82 |
| foundationone liquid cdx tmb | 1.57 | 0.5 | 9931 | 78 |
| foundationone cdx technical information | 0.63 | 0.3 | 3631 | 45 |
| foundation 1 liquid cdx | 1.6 | 0.6 | 33 | 54 |
| foundation medicine foundationone cdx | 0.17 | 0.4 | 7039 | 80 |
| what is foundationone cdx | 0.76 | 0.9 | 4499 | 86 |
| foundationone liquid cdx 保険収載 | 1.08 | 1 | 9175 | 44 |
| foundationone liquid cdx 保険適応 | 1.48 | 0.9 | 8127 | 62 |
| foundationone liquid cdx 保険点数 | 0.42 | 0.3 | 4444 | 22 |
The FoundationOne Liquid CDx test is used to test the blood of patients with metastatic castration resistant prostate cancer or non-small cell lung cancer.
What is the difference between guardant360 and FoundationOne Liquid CDX?Guardant360 CDx, made by Guardant Health, was approved as a companion diagnostic for osimertinib (Tagrisso), a lung cancer therapy. FoundationOne Liquid CDx, made by Foundation Medicine, was approved as a companion diagnostic for three lung cancer therapies and a prostate cancer therapy.
What's new with the expanded FDA approvals?Under the expanded approvals, announced by FDA in late October and early November, the use of the test as a companion diagnostic has been broadened to people with other cancers and other drugs not covered by the original approval. (See table.)
How is cfDNA used in the treatment of non-small cell lung cancer?The cfDNA is then separated from the plasma and mixed with chemical substances, called reagents, that find and test mutations in the MET gene. A medical professional reviews the results and sends a report to the patient’s doctor. The doctor uses this information to help manage the care of patients with non-small cell lung cancer.
